Product Description
For Chemotherapy Induced Neutropenia (Sourced from: https://www.google.com/search?client=safari&rls=en&q=da-3031+Dong-A&ie=UTF-8&oe=UTF-8)
Mechanisms of Action: G-CSF Antagonist
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Neutropenia
Phase 1: Lymphoma|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02963389 |
DA3031_PNP_I | P1 |
Completed |
Lymphoma |
2018-11-01 |
10% |
2019-03-21 |
|
NCT00959777 |
DA3031_NP_I | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-18 |
Treatments |
|
NCT01923545 |
PEG-G-CSF | P2 |
Completed |
Neutropenia |
2011-05-01 |
2019-03-19 |
Treatments |
|
NCT01674855 |
PEG-G-CSF | P3 |
Completed |
Neutropenia |
2013-02-01 |
2019-03-19 |